{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-020108","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.966328+00:00","generated_at":"2026-05-15T23:41:25.397322+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Edgewise reports Q4 net loss $50.2M ($0.47/sh); cash $530M; key trial readouts in 2026","bullets":["Net loss for Q4 2025 was $50.2M ($0.47/sh) vs $40.7M ($0.39/sh) in prior quarter; no revenue.","Cash, cash equivalents and marketable securities total $530.1M as of Dec 31, 2025.","GRAND CANYON top-line results for sevasemten in Becker expected Q4 2026; NDA submission H1 2027.","CIRRUS-HCM Part D 12-week data for EDG-7500 in HCM expected H1 2026; Phase 3 start H2 2026.","EDG-15400 Phase 1 healthy adult data H1 2026; Phase 2 in HFpEF planned H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-020108","json":"https://secwatch.observer/filing/0001104659-26-020108.json","markdown":"https://secwatch.observer/filing/0001104659-26-020108.md","text":"https://secwatch.observer/filing/0001104659-26-020108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000110465926020108/0001104659-26-020108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000110465926020108/tm266859d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:41:25.397322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}